More M&A Deals Could Boost Biotech ETFs

By
December 12, 2012
Share:

Amgen’s $415 million acquisition of DeCode suggests big-pharma will transition from blockbuster drugs to specialized medicines that target specific areas of the human body, a possibility that could bode well for the biotech sector and its ETFs, according to an article on ETF Trends.

The pursuit for targeted drugs could also benefit from the Obama administration’s push toward health care reform, as the extra insurance coverage would boost demand for medicines, the article said.

For investors seeking a doorway into biotech investments, consider these sector-covering ETFs as a starting point:

  • Market Vectors Biotech ETF (NYSEArca: BBH)
  • iShares Nasdaq Biotechnology ETF (NYSEArca: IBB)
  • First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT)

 

Head over to ETFtrends.com to learn more about ETFs within the biotech sector.

ETF.COM CHANNELS

Trying to figure out alternatives ETFs? Use our alternatives ETFs channel, library and ETF screener!

Want to learn more about smart-beta ETFs? Check out our smart-beta guide, essentials library and ETF screener!

ETF DAILY DATA

The broad-market 'SPY' and energy ETF 'XLE' were the biggest winners in terms of inflows on Thursday, Aug. 27.

The top three ETF issuers all saw net inflows into their products as the market surged on Thursday, Aug. 27.

ETF.COM ANALYST BLOGS

By Dave Nadig

With many ETFs currently trading well off fair value, what’s an ETF investor to do? Don’t panic.

By Matt Hougan

Out-of-favor funds can bring attractive returns.

By Matt Hougan

New data from Charles Schwab show that the death of mutual funds is happening faster than we thought.

By Dave Nadig

Grab the popcorn. Precidian just doubled-down on its nontransparent active ETF proposal with the SEC this morning.

ETF INDUSTRY PERSPECTIVE

By John Del Vecchio

An index that goes long financially sound companies and shorts the ones with problematic balance sheets.

By Dan Draper

The nature of retirement is changing. How can investors adapt?

By Invesco PowerShares

A more in-depth look at the smart-beta survey's results.